GENB Stock — Generate Biomedicines Inc.: Cash, EV, Pipeline

Share price

$17.14

Market cap

$2,200.0M

Cash

$457.4M

Enterprise value

$1,742.6M

Balance sheet

Cash	$457.4M
Debt	$0.0M
Net cash	$457.4M
Enterprise value	$1,742.6M
Basic shares	128.3M shares
Fully diluted shares	159.9M shares
Fully diluted market cap	$2,740.3M
Cash per share	$3.57

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading GENB daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 11 - Nov 22	GB-7624	Phase 1	Atopic Dermatitis (AD)	—
Jun 12 - Jul 24	GB-0895 (SC)	Phase 1	Asthma; COPD (Chronic Obstructive Pulmonary Disease)	—
Jul 13 - Aug 24	GB-4362	Phase 1	Advanced Urothelial Cancer; Metastatic Urothelial Carcinoma	—
Jan 12 - Feb 23	GB-0895	Phase 3	Severe Asthma	—
Feb 12 - Mar 26	GB-0895	Phase 3	Severe Asthma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

GB-0895

Phase 3 · Active

Target TSLP

Indications

Severe asthma (Phase 3)

Status note Lead candidate; ongoing Phase 3 clinical trials enrolling globally; company intends to prioritize GB-0895 for severe asthma. No modality or target disclosed in the excerpts. Platform-level collaborations (Novartis, Amgen, MD Anderson, Roswell Park, Flagship/PMCo) are not stated to cover GB-0895.

GB-4362

Stage not disclosed · Active

Target MMAE

Indications

Advanced Urothelial Cancer (Phase 1)
Metastatic Urothelial Carcinoma (Phase 1)

Status note Named as a product candidate in risk factors; no indication, stage, modality, or target disclosed in the excerpts.

GB-5267

Stage not disclosed · Active

Target MUC16

Indications

Platinum-resistant Ovarian Cancer (Phase 1)

Status note Named as a product candidate in risk factors; no indication, stage, modality, or target disclosed in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	GB-0895
Lead indication	Severe Asthma
Lead phase	Phase 3
Active trials	5
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07276724	Phase 3	Recruiting	Sponsor	GENB	—	Severe Asthma	—
NCT07359846	Phase 3	Recruiting	Sponsor	GENB	—	Severe Asthma	—
NCT07116889	Phase 1	Active, not recruiting	Sponsor	GENB	—	Asthma; COPD (Chronic Obstructive Pulmonary Disease)	—
NCT07484022	Phase 1	Recruiting	Sponsor	GENB	—	Advanced Urothelial Cancer; Metastatic Urothelial Carcinoma	—
NCT06920693	Phase 1	Active, not recruiting	Sponsor	GENB	—	Atopic Dermatitis (AD)	—
NCT07489287	Phase 1	Recruiting	Collaborator	Roswell Park Cancer Institute	—	Platinum-resistant Ovarian Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Generate Biomedicines on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Braidwell LP	3,283,844	-309,155	2.05%	2026-08-14
Baker Bros. Advisors	1,423,602	no change	0.12%	2026-08-14
Sphera Biotech	245,000	+60,000	0.59%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

GENB — Generate Biomedicines Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders